Design Therapeutics (DSGN) EBIT Margin (2020)
Design Therapeutics (DSGN) reported EBIT Margin of 11700.0% for Q4 2020, up 1.8% sequentially from 11915.0% in Q3 2020.
Design Therapeutics (DSGN) EBIT Margin (2020) Analysis & Trends
Design Therapeutics (DSGN) has 1 years of EBIT Margin data on file, last reported at 11700.0% in Q4 2020.
- For the quarter ending Q4 2020, EBIT Margin changed N/A year-over-year to 11700.0%; the trailing twelve-month figure through Dec 2020 stood at 3685.84% (changed N/A YoY), and the FY2020 full-year result was 3685.84%, changed N/A from the prior year.
- EBIT Margin climbed to 11700.0% in Q4 2020, from 11915.0% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 438.73% in Q1 2020 to a low of 11915.0% in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Design Therapeutics | 714.48 Mn | 491.66 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | -11,700.00% |
| Sep 30, 2020 | -11,915.00% |
| Jun 30, 2020 | -4,719.35% |
| Mar 31, 2020 | -438.73% |